Rifton Equipment recalled 1,096 units of the Low Base TRAM on December 18, 2025, due to a potential fraying hazard on the body support strap. The recall affects models distributed worldwide, including the US, Canada, and several countries in Europe and Asia. Patients and healthcare providers are advised to stop using this device immediately.
Potential for fraying on the body support strap.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Community Products, LLC or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the Low Base TRAM, Model/Catalog Number K320, with ID Codes ranging from K32020130515AA to K32020130812AB. The device is designed for transferring clients in a seated position and assisting in sit-to-stand transfers. It has been distributed worldwide, including in the US, UAE, Australia, Canada, EU, and others.
The body support strap on the Low Base TRAM may fray, posing a risk of failure during use. This defect could lead to serious injury for patients being transferred, as the support strap may not adequately secure them.
Currently, the recall has not reported any specific incidents or injuries related to the fraying hazard. However, the potential for harm is considered high due to the nature of the device's use in patient transfers.
Stop using the Low Base TRAM immediately. Contact Community Products, LLC or your healthcare provider for further instructions and follow the recall notice provided by the manufacturer.
For more information, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-1138-2026. Patients can also reach out directly to Community Products, LLC.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.